Drug Comparisons, Equivalents & Conversion Tools
Medication-equivalence calculators, potency comparisons, therapeutic-selection tools, opioid and benzodiazepine converters, cardiovascular drug comparisons, ophthalmic comparisons, corticosteroid conversions, interaction resources, and supporting GlobalRPh drug-reference tools.
Clinical background
“Equivalent” does not always mean interchangeable
Drug comparisons can answer several different clinical questions. One tool may estimate a dose with similar pharmacologic potency, another may compare expected class effects, and another may convert an exposure into a standardized measure such as morphine milligram equivalents. Those are related concepts, but they are not the same.
This portal brings the GlobalRPh comparison tools into one place and separates true dose-conversion resources from broader treatment-selection and drug-class references. Whenever a conversion is used clinically, the result should be interpreted in the context of indication, route, formulation, renal and hepatic function, drug interactions, prior exposure, therapeutic window, and patient-specific response.
- Estimated dose equivalence
- Relative pharmacologic potency
- Class-to-class selection
- MME / equianalgesic conversion
- Therapeutic-effect comparison
- Interaction & metabolism context
- Formulation / preservative comparison
- Monitoring & drug-level support
Use comparison tools safely
Three questions to ask before applying a conversion
CDC Updated 2022 Morphine Milligram Equivalents Calculator
This newer GlobalRPh MME calculator should be the prominent opioid-exposure resource on the Drug Comparisons portal. It allows entry of multiple commonly prescribed opioids and presents standardized morphine milligram equivalents while emphasizing the limitations of equianalgesic ratios.
Cytochrome P450 Analysis Tool
Drug equivalence can become misleading when metabolism differs because of inhibition, induction, pharmacogenomic variation, or interacting therapy. The GlobalRPh CYP450 tool provides a useful companion resource when comparing or switching medications.
Cardiovascular medication comparisons
ACE inhibitors, ARBs, beta blockers and statins
These long-standing GlobalRPh tools formed the core of the original Drug Comparisons portal and remain useful reference points when their approximate nature and clinical context are understood.
Renin-angiotensin system
Beta blockers
Statins & lipid therapy
- Statins – Historical Equivalent-Dose Table
- Statin Drug Reference
- Cardiovascular Risk & Advanced Lipid Analyzer
CNS & psychiatry
Benzodiazepines, antidepressants and medication-burden context
Benzodiazepine conversion
Antidepressant comparison & selection
Whole-list medication review
Pain management & opioid conversion
MME, opioid rotation, fentanyl and NSAID selection
Morphine milligram equivalents
Opioid rotation & advanced conversion
Non-opioid pain selection
Corticosteroids & dermatology
Systemic glucocorticoid conversion and topical potency
Systemic corticosteroids
Topical corticosteroid potency
Related dermatology portal
Gastroenterology
Acid-suppression comparisons
Proton pump inhibitors
Related acid-suppression class
Ophthalmology comparisons
Glaucoma potency, product selection and preservative options
Comparative effectiveness
Preservative & tolerability options
Ophthalmic drug library
Selection, interactions & verification
Resources that help interpret a drug comparison
A conversion is more useful when it is paired with information about interactions, monitoring, organ function, treatment appropriateness and the complete medication list.
Interaction analysis
Monitoring & organ function
Medication appropriateness & full references
Comparative therapeutics
Recent GlobalRPh articles that compare treatment strategies
Planned GlobalRPh updates
Areas we’re continuing to improve in the Drug Comparisons library
GlobalRPh has maintained many of these comparison tools for years. As we work through this section, we plan to update the underlying references, clarify when an “equivalent dose” is only an estimate, retire obsolete product information, and make the highest-risk conversions easier to verify.
Pages we plan to refresh
- ACE inhibitor equivalents: we plan to re-check the estimated conversion relationships against current labeling and contemporary hypertension, heart-failure and kidney-disease use.
- ARB equivalent doses: the current page still cites package inserts from the 2003-2007 era. We plan to refresh product availability, indications, dose ranges and the explanation of what the equivalence table can and cannot represent.
- Beta blocker equivalents: this is a high-priority update because the current page explicitly states that additional sources were not found to validate the listed equivalent doses. We plan to reassess the conversion framework rather than simply update formatting.
- Statin comparisons: we plan to shift the emphasis from older tablet-dose equivalence tables toward current statin intensity, expected LDL-C lowering, interaction limits, renal considerations and contemporary lipid-management use.
- Proton pump inhibitor comparisons: we plan to update the evidence behind acid-suppression and clinical-effect comparisons and make indication and dose-frequency differences more explicit.
- Benzodiazepine conversion: we plan to strengthen the explanation of approximate diazepam-equivalent dosing, long half-lives, active metabolites, tapering limitations and high-risk switching situations.
- Opioid conversions: we plan to further consolidate the older opioid tools around the newer 2022 CDC MME resource while keeping a separate distinction between MME calculations and true opioid rotation / equianalgesic decision-making.
- Topical corticosteroids: we plan to refresh both the potency selector and seven-group table with current products, vehicles and site-specific safety considerations.
- Glaucoma comparison tools: we plan to update the medication classes, preservative-free and BAK-free options, product availability, potency assumptions and newer agents.
- Antidepressant comparisons: we plan to update the approximate-equivalence table and treatment-selection app so newer agents, switching strategies, organ-function considerations and discontinuation risks are easier to interpret.
- CYP450 and drug-food interaction resources: we plan to expand current interaction coverage and make it easier to connect metabolism differences with medication selection and dose conversion.
Verification resources
Check the comparison against the current drug record
Supporting GlobalRPh resources
Additional clinical tools
Drug monitoring
Calculators & conversion archives
Complete site directories
Hospital protocols: useful historical resource, but not a drug-equivalence standard
The original Drug Comparisons portal linked the GlobalRPh hospital-protocol collection. We have retained that link because it remains useful for historical preparation, dosing and workflow examples, but submitted protocols should be verified against current labeling, guidelines and local institutional policy before clinical use.
